COSCIENS Biopharma Inc. (CSCI)

CA — Healthcare Sector

Peers:

Automate Your Wheel Strategy on CSCI

With Tiblio's Option Bot, you can configure your own wheel strategy including CSCI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CSCI
Rev/Share 2.8701
Book/Share 3.2259
PB 1.1206
Debt/Equity 0.2194
CurrentRatio 2.8834
ROIC -0.8483

MktCap 11375574.0
FreeCF/Share -4.8499
PFCF -0.7459
PE -0.6477
Debt/Assets 0.0715
DivYield 0
ROE -1.0095

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 4
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

CSCI
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.(“Goodwood”) regarding six (6) director nominations for the Company's upcoming Annual and Special Meeting of Shareholders.

image for news COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

CSCI
Published: March 19, 2025 by: Newsfile Corp
Sentiment: Neutral

Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced that there is a potential for delay in the filing of: (a) its annual financial statements as of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022, and its related management's discussion and analysis (collectively, the "Financial Statements"); (b) the CEO and CFO certificates relating to the Financial Statements; and (c) the Company's annual information …

image for news COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

About COSCIENS Biopharma Inc. (CSCI)

IPO Date 1996-07-18
Website https://www.cosciensbio.com
Industry Biotechnology
CEO Ms. Anna Elizabeth Biehn
Employees 40

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.